Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 6:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Biological: COVID-19 convalescent plasma Clear all
No Longer Available No phase listed Expanded access

Expanded Access to Convalescent Plasma to Treat and Prevent Pulmonary Complications Associated With COVID-19

NCT04358211
View directory record Official record
Conditions
COVID-19
Interventions
Biological: COVID-19 convalescent plasma
Biological
Lead sponsor
Nakhle Saba, MD
Other
Eligibility
18 Years and older
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Oct 3, 2026, 6:19 PM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19

NCT04338360
View directory record Official record
Conditions
COVID19
Interventions
COVID-19 convalescent plasma
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
U.S. locations
12
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 3, 2026, 6:19 PM EDT
Completed Phase 2 Interventional Results available

Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients

NCT04421404
View directory record Official record
Conditions
COVID-19, Sars-CoV2
Interventions
COVID-19 Convalescent Plasma (CCP), Placebo
Biological
Lead sponsor
Priscilla Hsue, MD
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2022 · Synced Oct 3, 2026, 6:19 PM EDT
Completed Phase 1 Interventional

Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019)

NCT04554992
View directory record Official record
Conditions
Covid19
Interventions
COVID 19 Convalescent Plasma
Biological
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 3, 2026, 6:19 PM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 3, 2026, 6:19 PM EDT
Terminated Early Phase 1 Interventional

Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure

NCT04353206
View directory record Official record
Conditions
Covid-19, Sars-CoV2
Interventions
Multiple Doses of Anti-SARS-CoV-2 convalescent plasma
Biological
Lead sponsor
Noah Merin
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Los Angeles, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 3, 2026, 6:19 PM EDT
Completed No phase listed Observational Results available

Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19

NCT04545047
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19)
Interventions
COVID-19 convalescent plasma
Biological
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 80 Years
Enrollment
5,044 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 3, 2026, 6:19 PM EDT
Terminated Phase 2 Interventional Results available

ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS)

NCT04432272
View directory record Official record
Conditions
COVID-19, Severe Acute Respiratory Syndrome (SARS), Coronavirus Infections
Interventions
COVID-19 convalescent plasma
Biological
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 3, 2026, 6:19 PM EDT
Terminated Phase 3 Interventional Results available

VA CoronavirUs Research and Efficacy Studies-1

NCT04539275
View directory record Official record
Conditions
COVID-19
Interventions
Convalescent Plasma, Masked Saline Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2022 · Synced Oct 3, 2026, 6:19 PM EDT
Completed Early Phase 1 Interventional

COVID-19 Convalescent Plasma (CCP) Transfusion

NCT04412486
View directory record Official record
Conditions
COVID-19
Interventions
COVID Convalescent Plasma
Biological
Lead sponsor
Gailen D. Marshall Jr., MD PhD
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 3, 2026, 6:19 PM EDT
Completed Phase 1 Interventional Results available

COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.

NCT04397757
View directory record Official record
Conditions
COVID-19
Interventions
COVID-19 Convalescent Plasma
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 3, 2026, 6:19 PM EDT
Completed Phase 2 Interventional Results available

Convalescent Plasma to Limit SARS-CoV-2 Associated Complications

NCT04373460
View directory record Official record
Conditions
SARS-CoV 2
Interventions
SARS-CoV-2 convalescent plasma, Plasma from a volunteer donor
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
1,225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
29
States / cities
Birmingham, Alabama • Chinle, Arizona • Phoenix, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2023 · Synced Oct 3, 2026, 6:19 PM EDT
No Longer Available No phase listed Expanded access

Investigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 Patients

NCT04420988
View directory record Official record
Conditions
COVID-19, SARS-CoV 2, SARS-CoV Infection
Interventions
COVID-19 Convalescent Plasma
Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 3, 2026, 6:19 PM EDT
Completed Early Phase 1 Interventional

CoVID-19 Plasma in Treatment of COVID-19 Patients

NCT04355897
View directory record Official record
Conditions
COVID 19
Interventions
Convalescent COVID 19 Plasma
Biological
Lead sponsor
The Christ Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Cincinnati, Ohio • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 3, 2026, 6:19 PM EDT
Withdrawn Phase 1 Interventional

Intermediate IND Severe Illness COVID-19 CP

NCT04411602
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome, COVID
Interventions
SARS-CoV-2 plasma
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Novi, Michigan • Southfield, Michigan • Warren, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 3, 2026, 6:19 PM EDT
Completed Phase 1 Interventional Results available

COVID-19 Convalescent Plasma for Mechanically Ventilated Population

NCT04388527
View directory record Official record
Conditions
Covid-19
Interventions
COVID-19 Convalescent Plasma
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 3, 2026, 6:19 PM EDT
No Longer Available No phase listed Expanded access

Convalescent Plasma for the Treatment of Patients With COVID-19

NCT04372368
View directory record Official record
Conditions
COVID-19, SARS-CoV 2
Interventions
COVID-19 Convalescent Plasma
Biological
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
U.S. locations
6
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2020 · Synced Oct 3, 2026, 6:19 PM EDT
Completed Phase 2Phase 3 Interventional

The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol

NCT04349410
View directory record Official record
Conditions
CoVid 19 Positive
Interventions
Hydroxychloroquine, Azithromycin, Hydroxychloroquine, Doxycycline, Hydroxychloroquine, Clindamycin, Hydroxychloroquine, Clindamycin, Primaquine - low dose., Hydroxychloroquine, Clindamycin, Primaquine - high dose., Remdesivir, Tocilizumab, Methylprednisolone, Interferon-Alpha2B, Losartan, Convalescent Serum
Drug
Lead sponsor
The Camelot Foundation
Other
Eligibility
Not listed
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Oct 3, 2026, 6:19 PM EDT